크로만 유도체 및 이를 유효성분으로 함유하는 신생혈관성 안질환 또는 암의 예방 또는 치료용 약학적 조성물
申请人:Gachon University of Industry-Academic cooperation Foundation 가천대학교 산학협력단(220040376324) BRN ▼129-82-07687
公开号:KR20200124630A
公开(公告)日:2020-11-03
본 발명은 크로만 유도체인 하기 화학식 1의 화합물, 이의 수화물, 이의 입체 이성질체, 또는 이의 약학적으로 허용 가능한 염을 포함하는 암 또는 신생혈관과 관련된 질환 치료용 약학적 조성물을 제공한다. [화학식 1] (상기 화학식 1에서 R, R, R, R, R, R, R은 발명의 설명에서 정의한 바와 같다.)
The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia.
1,6-Dipolar cycloadditions represent a valuable strategy for the rapid construction of medium-sized rings. Herein, we describe the concept for the design of 1,6-dipoles that bypasses the regioselectivity. Through the introduction of an amino group into Morita–Baylis–Hillman (MBH) carbonates, unprecedented [6 + 2] dipolarcycloadditions were accurately developed with Cs2CO3, efficiently delivering a
DABCO catalyzed [4+2] annulations of Morita–Baylis–Hillman carbonates with isocyanates
作者:Wei Cai、Yiming Zhou、Yanlin He、You Huang
DOI:10.1039/d1cc03502a
日期:——
A highly concise method for 1,4-diazabicyclo[2.2.2]octane (DABCO) catalyzed [4+2] annulations of o-amino-acylation of aryl MBH carbonates with isocyanates has been developed. For the first time, MBH carbonates served as 1,4-dipoles, providing functionalized 3,4-dihydroquinazolinones in mild conditions with good to excellent yields. The density functional theory calculations of the mechanism supports
[EN] TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS<br/>[FR] ANTAGONISTES DE TRPM8 ET LEUR UTILISATION DANS LE CADRE THÉRAPEUTIQUE
申请人:AMGEN INC
公开号:WO2012177896A1
公开(公告)日:2012-12-27
Compounds of Formula (I) are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula (I) have the above structure, where the definitions of the variables are provided herein.